Stock fact sheet · data as of
Tekla Life Sciences Investors (HQL): fair value, margin of safety and Wheel Score
Financial Services · Asset Management · United States · High Yield Income
Is HQL undervalued?
HQL has a margin of safety of 90%: the stock closed at 17.24 on 16 Oct 2026 against a GLS average fair value of 165.23. 7 of the 7 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between DDM (32.96) and GLS Growth (398.97). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files HQL under High Yield Income: a dividend yield above 4%.
Nine valuation models for HQL
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 64.58 | +275% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 52.00 | +202% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 372.77 | +2062% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 162.92 | +845% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 398.97 | +2214% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | 32.96 | +91% | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend |
| EPV | 72.41 | +320% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.0156 | -100% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Tekla Life Sciences Investors scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 4.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 16.7%, ROE 16.7%, ROA 16.6% - with debt at 0.00 times equity and negative free cash flow.
The dividend yield is high at 12.99% (payout ratio 25%). A yield this size is often the market's way of pricing a risk to the payout, so the health score and cash flow matter more than usual.
Institutional ownership scores 3/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | 16.7% |
|---|---|---|---|
| GLS Moat | 4.5 / 10 | ROE | 16.7% |
| Debt / equity | 0.00 | ROA | 16.6% |
| Free-cash-flow yield | -0.5% | Payout ratio | 25% |
| Institutions | 3 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 39: No options
No options are listed on Tekla Life Sciences Investors in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.
Volume runs at 102k shares a day on a market cap of $524M, with a beta of 0.73 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 7 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 90% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 7 / 15 | moat 4.5/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 7 / 20 | 102k shares/day, $524M cap, beta 0.73 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for HQL in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Asset Management
The 12 companies below are the closest to Tekla Life Sciences Investors by market cap within the Asset Management industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| GUT The Gabelli Utility Trust | 5.85 | 10.76 | +46% | 39No options | $524M |
| PFESX PFG BR Target Allocation Equity Strategy Fund Class I | 19.11 | 58.45 | +67% | 39No options | $522M |
| HNCAX Hartford International Growth Fund Class A | 22.24 | 2.17 | -927% | 21No options | $522M |
| CCID Carlyle Credit Income Fund | 24.94 | 24.99 | +0% | 23No options | $529M |
| ABHYX American Century High-Yield Municipal Fund Investor Class | 8.26 | 15.22 | +46% | 39No options | $518M |
| BTBFX Boston Trust Asset Management Fund | 64.34 | 1,713.01 | +96% | 39No options | $516M |
| AIOIX American Century Intl Opportunities - Investor Class | 12.74 | 7.22 | -76% | 21No options | $533M |
| MSIF MSC Income Fund, Inc. | 11.79 | 30.81 | +62% | 39No options | $535M |
| STSGX American Beacon Stephens Small Cap Growth Fd Inv Cl | 13.33 | 4,803.15 | +100% | 39No options | $513M |
| NCDL Nuveen Churchill Direct Lending Corp. | 10.86 | 51.49 | +79% | 39No options | $536M |
| MMU Western Asset Managed Municipals Fund | 9.36 | 22.86 | +59% | 39No options | $511M |
| ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund | 8.00 | 9.27 | +14% | 36No options | $538M |
⚖ Compare HQL with 7 of them All Financial Services stocks →
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about HQL
Is HQL undervalued right now?
By the GLS models, yes: at 17.24 the stock is 90% below the average fair value of 165.23 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of HQL and what does it mean?
HQL has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for HQL?
165.23 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Tekla Life Sciences Investors report earnings next?
No upcoming earnings date is recorded for HQL in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does HQL have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on HQL, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.